How is non–small cell lung cancer (NSCLC) treated in patients with BRAF mutation?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

Treatment for NSCLC with BRAF mutation is with dabrafenib (Tafinlar) in combination with trametinib (Mekinist).


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!